Nelson Dusetti, Research Director at INSERM, shared a post on LinkedIn:
“Poster spotlight: ‘Tracking genome evolution and chemoresistance in pancreatic cancer’ (AACR B129)
At the AACR Special Conference on Pancreatic Cancer (Boston, Sept 28–Oct 1, 2025), Audrey Lumeau and Sarah McClelland (Barts Cancer Institute, Queen Mary University of London) are presenting exciting work on how chromosomal instability (CIN) and evolving copy number alterations shape chemoresistance in pancreatic ductal adenocarcinoma.
This study dissects clonal selection under gemcitabine pressure, showing how resistant clones emerge and how certain genomic alterations may explain long-term survival in some patients treated with specific drugs.
Collaborating in this effort reaffirms our commitment to precision oncology using molecular signatures to understand which patients will benefit from particular chemotherapies, and ultimately to overcome drug resistance.
The project reflects a fruitful collaboration between Barts Cancer Institute (Queen Mary University of London), the CRCM – Cancer Research Center of Marseille and the Paoli Calmettes Institute (IPC).
I am glad to have contributed as a collaborator and warmly congratulate Audrey, Sarah, and the whole team for driving this important research forward.”
Read more posts featuring Nelson Dusetti on OncoDaily.